MMH-MAP(MMH-MAP) - 在研适应症：缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Prospecta

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病心血管疾病

在研适应症

缺血性卒中

非在研适应症

轻度认知障碍

原研机构

OOO NPF Materia Medica Holding

在研机构

OOO NPF Materia Medica Holding

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 MMH-MAP 相关的临床试验

EUCTR2021-002366-41-IT

/ Unknown status临床2期IIT

Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma - AIEOP-ISG OsM+

开始日期2021-09-28

申办/合作机构

Associazione Italiana Di Oncologia Medica

NCT04295681

/ Completed临床3期

A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries

The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.

开始日期2019-12-12

申办/合作机构

OOO NPF Materia Medica Holding

NCT03815292

/ Completed临床3期

Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke

The purpose of this study is:
to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke
to evaluate safety of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke

开始日期2018-10-19

申办/合作机构

OOO NPF Materia Medica Holding

100 项与 MMH-MAP 相关的临床结果

登录后查看更多信息

100 项与 MMH-MAP 相关的转化医学

登录后查看更多信息

100 项与 MMH-MAP 相关的专利（医药）

登录后查看更多信息

1

项与 MMH-MAP 相关的文献（医药）

2021-01-01·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke

Article

作者: Belova, A N ; Zhadnov, V A ; Voznyuk, I A ; Kurushina, O V ; Bogdanov, E I ; Kamchatnov, P R ; Maslova, N N

OBJECTIVETo assess the efficacy and safety of prospecta in the treatment of moderate cognitive impairment in the early recovery period of ischemic stroke.MATERIAL AND METHODSThe study included 275 patients (mean age 64.0±8.1 years) with a history of single ischemic stroke from 3 to 6 months, with moderate cognitive impairment, and moderate activity in everyday life, who were randomized in two groups. During the screening phase, the severity of cognitive impairment was assessed with the Mini-Mental State Examination and Montreal Cognitive Assessment scales; the level of activity in everyday life was evaluated with the Barthel Scale; and quality of life was assessed with the Stroke Specific Quality of Life Scale. Patients took 2 tablets of prospecta or placebo 2 times a day for 24 weeks. The follow-up period was 4 weeks. The primary endpoint of the study was the proportion of patients with improvement in cognitive function (+1 or more on the MoCA test) after 24 weeks of treatment. The occurrence and type of adverse events (AEs), their severity, relationship to the drug, outcome, changes in vital signs, and the proportion of patients with clinically significant abnormality in laboratory tests were analyzed to assess the safety.RESULTSA clinically significant improvement in cognitive function was obtained in 91.9% of patients in the prospecta group vs 82.,1% in the placebo group, (p=0.02). There were 57 AEs in 37 (27.4%) Prospecta group patients and 53 AEs in 39 (27.9%) Placebo group participants (p=1.00). No AEs were certainly associated with taking the medication. No clinically significant changes in vital signs or abnormal laboratory results were detected during the study.CONCLUSIONProspecta is an effective and safe treatment option for patients with moderate cognitive impairment in the early recovery period of ischemic stroke.

100 项与 MMH-MAP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺血性卒中	临床3期	俄罗斯	OOO NPF Materia Medica Holding	2018-10-19
轻度认知障碍	临床2期	俄罗斯	OOO NPF Materia Medica Holding	2018-10-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04295681 (CTgov)	临床3期	认知功能障碍 \| 缺血性卒中	246	MMH-MAP (MMH-MAP)	醖築鏇觸鏇積膚網膚鑰(網窪憲簾遞壓顧醖鹹顧) = 廠膚膚繭鏇獵顧窪夢鹽鹽製淵積廠醖憲廠廠構 (鏇鹹壓觸夢構夢鏇廠醖, 鏇夢膚窪鑰獵夢膚築構 ~ 餘蓋範鑰鏇顧蓋鑰憲顧) 更多	-	2024-10-28
				Placebo (Placebo)	醖築鏇觸鏇積膚網膚鑰(網窪憲簾遞壓顧醖鹹顧) = 觸憲壓網簾壓範壓廠繭鹽製淵積廠醖憲廠廠構 (鏇鹹壓觸夢構夢鏇廠醖, 糧選獵齋構醖顧壓衊鹽 ~ 積繭願壓窪憲蓋積糧鹹) 更多
NCT03815292 (CTgov)	临床3期	缺血性卒中 \| 轻度认知障碍	276	MMH-MAP (MMH-MAP)	壓壓願齋壓範窪獵襯艱(蓋鬱鏇製蓋齋製積觸鹽) = 構積膚製鬱鑰願築膚蓋網願繭齋鏇廠獵鏇鬱壓 (憲遞憲簾夢壓鏇範醖餘, 壓鹽簾鏇艱餘窪衊襯鹹 ~ 築簾壓窪鑰艱醖壓簾選) 更多	-	2021-02-23
				Placebo (Placebo)	壓壓願齋壓範窪獵襯艱(蓋鬱鏇製蓋齋製積觸鹽) = 蓋構淵夢鑰衊膚窪製糧網願繭齋鏇廠獵鏇鬱壓 (憲遞憲簾夢壓鏇範醖餘, 醖製壓簾顧襯繭齋襯艱 ~ 鑰膚糧網壓膚網醖糧繭) 更多